Company Directory / biotech/health
PrivateFor profitbiotech/healthLiege, Belgium
Imcyse
Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.
- Founded
- 2010 16 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $56M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
16 years old.
Reach
Website ranked #5,464,711 in the world for traffic, about 1k visits a month.
What it does
BiotechnologyPharmaceuticalTherapeutics
Funding, as listed
$56M currency not stated
- Rounds4
- LatestSeries b, Feb 2021
- Investors10, 4 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Imcyse, field by field. Contact details are held but never shown.
The company
- Name
- Imcyse
- Type
- For profit
- Status
- Private
- Founded
- 2010
- Founders
- Vincent Carlier
- Industry
- biotech/health
- Categories
- Biotechnology, Pharmaceutical, Therapeutics
Where
- City
- Liege
- Country
- Belgium
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #5,464,711
- Monthly web visits
- 1,349
Funding, as listed
- Total
- 55,900,000 (currency not stated)
- Rounds
- 4
- Latest round
- Series b
- Latest round date
- Feb 2021
- Investors
- 10
- Lead investors
- 4
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Imcyse may be growing as it is listed among companies in a market that is expected to see further growth, specifically in the global diabetes drug market. The company is also mentioned in the context of the diabetic peripheral neuropathy market, which is growing at a CAGR of approximately 6% by 2032, indicating a positive trend in the industry that Imcyse is part of. Furthermore, Imcyse is named alongside major players in the type 1 diabetes market, which is predicted to accelerate substantially during the study period of 2019-2032, suggesting that the company is active in a dynamic and expanding market segment.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
biotech/health in Belgium.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,920 companies in Belgium and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.